Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications.

Abstract

This meta-analysis evaluated the frequency of neutralizing antibody (nAb) conversion with onabotulinumtoxinA (BOTOX®; Allergan) across five studied indications. The analysis was based on large, controlled or prospective, open-label trials (durations 4 months to ≥2 years). Serum samples were analyzed for nAbs using the Mouse Protection Assay. Subjects who… (More)
DOI: 10.1002/mds.23254

Topics

Cite this paper

@article{Naumann2010MetaanalysisON, title={Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications.}, author={Markus G Naumann and Alastair Carruthers and Jean Diana Carruthers and Sheena K. Aurora and Ross Zafonte and Susan Abu-Shakra and Terry I Boodhoo and Mary Ann Miller-Messana and George Demos and L. Douglas James and Frederick C. Beddingfield and Amanda M Vandenburgh and Mary Ann Chapman and Mitchell F. Brin}, journal={Movement disorders : official journal of the Movement Disorder Society}, year={2010}, volume={25 13}, pages={2211-8} }